Manhattan Eye, Ear & Throat Hospital
New York, 10021, United States
NCT Number: NCT00211458
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Phase 2
New York, 10021, United States
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Manhattan Eye, Ear & Throat Hospital
Other
Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05637255
Eye Diseases, Macular Degeneration
Brno, Czechia
View Trial DetailsNCT00527475
Eye Diseases, Macular Degeneration
Santa Barbara, California, United States
View Trial DetailsNCT05456581
Blindness, Blindness, Cortical
Birmingham, Alabama, United States
View Trial DetailsNCT04435366
Eye Diseases, Geographic Atrophy
Beverly Hills, California, United States
View Trial Details